There are no Focus articles on ICGN.
There are no Transcripts on ICGN.
Sep. 6, 2011, 1:45 PM
Aug. 29, 2011, 9:41 AM
Jul. 20, 2011, 10:20 AM
Jul. 20, 2011, 9:36 AMPfizer (PFE) is acquiring Icagen (ICGN), a developer of pain relief drugs, for $6/share. After accounting for Pfizer's current 11% stake in the company, the transaction will cost approximately $49.8M. Icagen, which closed yesterday at $7.75, is down 23.2% on the news. One legal firm is already announcing an investigation into the deal. | Comment!
Jun. 27, 2011, 9:07 AM
Feb. 2, 2011, 9:52 AMIcagen (ICGN) sees a strong open (+30%) as the FDA lifts a clinical hold on ICA-105665, the company's experimental drug for epilepsy. While serious questions may remain about the risk/reward profile of the drug, it would appear that Icagen will at least have the opportunity to collect more data. | Comment!
Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.
ICGN vs. ETF Alternatives
Other News & PR